

## Subjec Index

- Acyclic nucleotide analogue**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, HPMPA, HPMPA, PMEA, 295
- Acyclovir**, Recurrent genital herpes, Herpes simplex virus, Guinea pig model, 227
- (RS)-AHPA**, SAH hydrolase inhibitor, (RS)-DHPA, C-c3Ado, Plant virus, TMV, PVX, 219
- Antagonism**, **Synergism**, Antiviral combination experiment, Isobole method, Mathematical modeling, 23
- Anthraquinone**, Anti-HIV-1 activity, Reverse transcriptase, Hypericin, 265
- Anti-HIV-1 activity**, Anthraquinone, Reverse transcriptase, Hypericin, 265
- Antigen presentation**, Immunotherapy, HSV, Liposome, Recurrence, 187
- Antitherpes activity**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), dNTP pool, HSV-infected cell, 111
- Antirhinovirus agent**, Ro 09-0410, Chalcone amide, Binding site, Drug resitant HRV-2 subline, 61
- Antiviral combination experiment**, Synergism, Antagonism, Isobole method, Mathematical modeling, 23
- Antiviral agent**, Cytomegalovirus infection, Nucleoside analog, HPMPA, Cultured cell, Guinea pig, 237
- 2-5 As**, Dinucleotide, Vesicular stomatitis virus, RNA polymerase, Inhibition of RNA synthesis, 81
- Astrovirus**, Synthetic flavanoid, 201
- Asymptomatic HIV infection**, HIV-1 p24 antigenemia, Zidovudine treatment, 127
- Avian myeloblastosis virus**, Reverse transcriptase, Retrovirus, PMEA, 287
- ()-BHCG**, HSV-1, HSV-2, 43
- Binding site**, Antirhinovirus agent, Ro 09-0410, Chalcone amide, Drug resitant HRV-2 subline, 61
- C-c3Ado**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, Plant virus, TMV, PVX, 219
- Cat Mx protein**, Interferon, Feline viral disease, 53
- Cell-mediated immunity**, Measles virus, 75
- Chalcone amide**, Antirhinovirus agent, Ro 09-0410, Binding site, Drug resitant HRV-2 subline, 61
- CMV receptor**, Human CMV, Mouse CMV, Monkey CMV, 1
- Cultured cell**, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, HPMPA, Guinea pig, 237
- Cytomegalovirus infection**, Antiviral agent, Nucleoside analog, HPMPA, Cultured cell, Guinea pig, 237
- (RS)-DHPA**, SAH hydrolase inhibitor, (RS)-AHPA, C-c3Ado, Plant virus, TMV, PVX, 219
- Dengue**, Ribavirin, Rhesus monkey, 139
- Differentiation**, Human monocyte, Herpes simplex virus type 1, Interferon-, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Dinucleotide**, 2-5 As, Vesicular stomatitis virus, RNA polymerase, Inhibition of RNA synthesis, 81
- DNA polymerase inhibition**, Herpes simplex virus, Phosphonylmethoxyalkylpurine, -pyrimidine, HPMPA, PMEA, 209
- DNA topoisomerase II activity**, Hg cells, HIV-1, 273
- Drug resitant HRV-2 subline**, Antirhinovirus agent, Ro 09-0410, Chalcone amide, Binding site, 61
- Drug screening**, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon- $\alpha$ , Poly I:C-LC, acyclovir, Viability index, 175
- (E)-5-(2-bromovinyl)-2'-deoxycytidine**, Tetrahydrodeoxyuridine (deaminase inhibitor), Antitherpes activity, dNTP pool, HSV-infected cell, 111
- Enveloped virus**, Hypericin, Pseudophypericin, Virucidal agent, Non-enveloped virus, 313
- FEAU**, Hu rIFN, Simian varicella virus, Monkey, 165
- Feline viral disease**, Interferon, Cat Mx protein, 53
- Guanosine analog**, Nucleoside analog, Immune modulator, 91
- Guinea pig model**, Acyclovir, Recurrent genital herpes, Herpes simplex virus, 227
- Guinea pig**, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, HPMPA, Cultured cell, 237

- Herpes simplex virus**, Oligonucleotide inhibition, 151
- Herpes simplex virus type 1**, Human monocyte, Differentiation, Interferon- $\alpha$ , Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Herpes simplex virus**, DNA polymerase inhibition, Phosphonylmethoxyalkylpurine, -pyrimidine, HPMPA, PMEA, 209
- Herpes simplex virus**, Acyclovir, Recurrent genital herpes, Guinea pig model, 227
- Hg cells**, HIV-1, DNA topoisomerase II activity, 273
- HIV-1 p24 antigenemia**, Asymptomatic HIV infection, Zidovudine treatment, 127
- HIV-1**, Hg cells, DNA topoisomerase II activity, 273
- HPMPA**, DNA polymerase inhibition, Herpes simplex virus, Phosphonylmethoxyalkylpurine, -pyrimidine, PMEA, 209
- HPMPA**, HSV-1 encoded ribonucleotide reductase, Phosphonylmethyl derivative of acyclic nucleoside analog, PMEA, 253
- HPMPA**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, PMEA, 295
- HPMPC**, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, Cultured cell, Guinea pig, 237
- HPMPC**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, PMEA, 295
- HSV**, Immunotherapy, Liposome, Recurrence, Antigen presentation, 187
- HSV-1 encoded ribonucleotide reductase**, Phosphonylmethyl derivative of acyclic nucleoside analog, HPMPA, PMEA, 253
- HSV-1**, (-)-BHCG, HSV-2, 43
- HSV-2**, (-)-BHCG, HSV-1, 43
- HSV-infected cell**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, dNTP pool, 111
- Hu rIFN**, FEAU, Simian varicella virus, Monkey, 165
- Human CMV**, Mouse CMV, Monkey CMV, CMV receptor, 1
- Human monocyte**, Differentiation, Herpes simplex virus type 1, Interferon- $\alpha$ , Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Hypericin**, Anthraquinone, Anti-HIV-1 activity, Reverse transcriptase, 265
- Hypericin**, Pseudohypericin, Virucidal agent, Enveloped virus, Non-enveloped virus, 313
- Immune modulator**, Nucleoside analog, Guanosine analog, 91
- Immunomodulator**, Lipid A analogue, Interferon, Natural killer (NK) cell, 327
- Immunotherapy**, HSV, Liposome, Recurrence, Antigen presentation, 187
- Influenza virus**, Pine cone extract, RNA dependent RNA polymerase, Influenza, Nasal IgA, 103
- Inhibition of RNA synthesis**, 2-5 As, Dinucleotide, Vesicular stomatitis virus, RNA polymerase, 81
- Interferon**, Cat Mx protein, Feline viral disease, 53
- Interferon- $\alpha$** , Human monocyte, Differentiation, Herpes simplex virus type 1, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Interferon**, Immunomodulator, Lipid A analogue, Natural killer (NK) cell, 327
- Isobole method**, Synergism, Antagonism, Antiviral combination experiment, Mathematical modeling, 23
- Lipid A analogue**, Immunomodulator, Interferon, Natural killer (NK) cell, 327
- Liposome**, Immunotherapy, HSV, Recurrence, Antigen presentation, 187
- Mathematical modeling**, Synergism, Antagonism, Antiviral combination experiment, Isobole method, 23
- Measles virus**, Cell-mediated immunity, 75
- Monkey CMV**, Human CMV, Mouse CMV, CMV receptor, 1
- Monkey**, FEAU, Hu rIFN, Simian varicella virus, 165
- Mouse CMV**, Human CMV, Monkey CMV, CMV receptor, 1
- N-(2-phosphonylmethoxyethyl) derivative**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, Acyclic nucleotide analogue, HPMPA, HPMPA, PMEA, 295
- N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives**, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, HPMPA, PMEA, 295
- Nasal IgA**, Influenza, 103
- Natural killer (NK) cell**, Immunomodulator, Lipid A analogue, Interferon, 327
- Non-enveloped virus**, Hypericin, Pseudohypericin, Virucidal agent, Enveloped virus, 313
- dNTP pool**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, HSV-infected cell, 111

- Nucleoside analog**, Immune modulator, Guanosine analog, 91
- Nucleoside analog**, Cytomegalovirus infection, Antiviral agent, HPMPC, Cultured cell, Guinea pig, 237
- Oligonucleotide inhibition**, Herpes simplex virus, 151
- Phosphonylmethyl derivative of acyclic nucleoside analog**, HSV-1 encoded ribonucleotide reductase, HPMPA, PMEA, 253
- Pine cone extract**, Influenza virus, RNA dependent RNA polymerase, 11
- Plant virus**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, TMV, PVX, 219
- PMEA**, DNA polymerase inhibition, Herpes simplex virus, Phosphonylmethoxyalkylpurine,-pyrimidine, HPMPA, 209
- PMEA**, HSV-1 encoded ribonucleotide reductase, Phosphonylmethyl derivative of acyclic nucleoside analog, HPMPA, 253
- PMEA**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, HPMPC, 295
- PMEA**, Reverse transcriptase, Retrovirus, Avian myeloblastosis virus, 287
- Phosphonylmethoxyalkylpurine,-pyrimidine**, DNA polymerase inhibition, Herpes simplex virus, HPMPA, PMEA, 209
- Poly I:C-LC**, acyclovir, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon- $\alpha$ , Viability index, Drug screening, 175
- Pseudophycerpin**, Hypericin, Virucidal agent, Enveloped virus, Non-enveloped virus, 313
- PVX**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, TMV, 219
- RNA dependent RNA polymerase**, Influenza virus, Pine cone extract, 11
- RNA polymerase**, 2-5 As, Dinucleotide, Vesicular stomatitis virus, Inhibition of RNA synthesis, 81
- Recurrence**, Immunotherapy, HSV, Liposome, Antigen presentation, 187
- Recurrent genital herpes**, Acyclovir, Herpes simplex virus, Guinea pig model, 227
- Retrovirus**, Reverse transcriptase, PMEA, Avian myeloblastosis virus, 287
- Reverse transcriptase**, Anthraquinone, Anti-HIV-1 activity, Hypericin, 265
- Reverse transcriptase**, Retrovirus, PMEA, Avian myeloblastosis virus, 287
- Rhesus monkey**, Ribavirin, Dengue, 139
- Ribavirin**, Dengue, Rhesus monkey, 139
- Ro 09-0410**, Antirhinovirus agent, Chalcone amide, Binding site, Drug resistant HRV-2 subline, 61
- SAH hydrolase inhibitor**, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, TMV, PVX, 219
- Simian varicella virus**, FEAU, Hu rIFN, Monkey, 165
- Synergism**, Antagonism, Antiviral combination experiment, Isobole method, Mathematical modeling, 23
- Synthetic flavanoid**, Astrovirus, 201
- Tetrahydrodeoxyuridine (deaminase inhibitor)**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Antih herpes activity, dNTP pool, HSV-infected cell, 111
- TMV**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, PVX, 219
- Vesicular stomatitis virus**, 2-5 As, Dinucleotide, RNA polymerase, Inhibition of RNA synthesis, 81
- Viability index**, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon-, Poly I:C-LC, acyclovir, Drug screening, 175
- Virucidal agent**, Hypericin, Pseudophycerpin, Enveloped virus, Non-enveloped virus, 313
- Zidovudine treatment**, Asymptomatic HIV infection, HIV-1 p24 antigenemia, 127